Company intelligence / Profile preview

Zhongsheng Funojiansheng Biotechnology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Sino-Fronogen is a Chinese biotechnology company focused on the development of mRNA-based therapeutics and vaccines. A joint venture involving China National Biotec Group (CNBG), a subsidiary of Sinopharm, the company leverages advanced mRNA technology to address infectious diseases and other therapeutic areas. Its lead programs include mRNA vaccines for COVID-19, which have progressed into clinical trials. Sino-Fronogen aims to establish a robust domestic mRNA manufacturing and R&D infrastructure to support public health initiatives in China and globally.

Therapeutic areas: Infectious Diseases
Modalities: mRNA-based drugsVaccineBiologic
Industry: Biotech

Partnerships

SinopharmChina National Biotec Group (CNBG)

Beyond the preview

Go deeper on Zhongsheng Funojiansheng Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhongsheng Funojiansheng Biotechnology.

Explore the full profile